Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Reproductive system and breast disorders – page 35

  • 960 clinical trials
  • 390 recruiting
  • 346 conditions
  • 28 countries

Conditions in this area

346 conditions with trials, the busiest first

Breast cancer170Prostate cancer102Ovarian cancer90Breast cancer metastatic84Triple negative breast cancer69Hormone receptor positive HER2 negative breast cancer62Hormone-refractory prostate cancer56Endometrial cancer53Prostate cancer metastatic48HER2 positive breast cancer42Hormone receptor positive breast cancer42Cervix carcinoma35Fallopian tube cancer30Breast cancer female27Non-small cell lung cancer25Infertility female22Hormone-dependent prostate cancer19Infertility18Ovarian cancer recurrent18Ovarian epithelial cancer18Colorectal cancer12Gastric cancer12Head and neck cancer12Malignant peritoneal neoplasm12+322

Clinical trials in Reproductive system and breast disorders

960 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

960 clinical trials

Breast cancer+2

Not yet recruiting

Efficacy and Safety of Letrozole SIE Compared with Oral Letrozole, Both with Ribociclib, in Postmenopausal Women with HR‑Positive, HER2‑Negative Metastatic Breast Cancer

Registered drug
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Letrozole
  • Sponsor:Laboratorios Farmaceuticos Rovi S.A.

Malignant peritoneal neoplasm+2

Not yet recruiting

Azenosertib versus drug combination in platinum‑resistant high‑grade serous ovarian, fallopian tube or primary peritoneal cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Azenosertib
  • Sponsor:K-Group Beta Inc.

Hormone-refractory prostate cancer

Not yet recruiting

Phase III Randomized Open‑Label Trial of BNT324 vs Docetaxel Plus Prednisone in Patients with Metastatic Castration‑Resistant Prostate Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel
  • Sponsor:BioNTech SE

Hormone-dependent prostate cancer

Not yet recruiting

Feasibility of Sequential Radium Ra-223 Dichloride After Triplet Therapy in High‑Volume Metastatic Hormone‑Sensitive Prostate Cancer Patients (Phase II)

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Radium RA 223 dichloride

Breast cancer

Not yet recruiting

Phase II Study of [68Ga]Ga-FAP-2286 PET/CT for Staging and Restaging Newly Diagnosed Primary Breast Cancer Patients

InvestigationalNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Sponsor:Odense University Hospital

Hormone-refractory prostate cancer

Not yet recruiting

Phase II Study of Lutetium (177Lu) Zadavotide Guraxetan Radioligand Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer

InvestigationalNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Lutetium (177LU) zadavotide guraxetan
  • Sponsor:Region Uppsala

Triple negative breast cancer

Not yet recruiting

Assessing the prognostic value of PSMA‑T4 SPECT/CT imaging in patients with triple‑negative breast cancer undergoing neoadjuvant therapy

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:PSMA-T4
  • Sponsor:Narodowe Centrum Badan Jadrowych

Breast cancer

Not yet recruiting

Premedication with dexamethasone to prevent interstitial lung disease in breast cancer patients receiving trastuzumab deruxtecan

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Dexamethasone
  • Sponsor:Istituto Di Ricerche Farmacologiche Mario Negri

Triple negative breast cancer

Not yet recruiting

Carboplatin drug combination as neoadjuvant therapy for early stage II triple‑negative breast cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Institut Paoli-Calmettes

Adrenogenital syndrome

Not yet recruiting

Study of Crinecerfont in Adults with Classic Congenital Adrenal Hyperplasia to Reduce Androgen Levels

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:18–64 years
  • Substances:Crinecerfont
  • Sponsor:Neurocrine Biosciences Inc.

Lichen sclerosus

Not yet recruiting

A Phase 3 Study of Delgocitinib Cream to Evaluate Efficacy and Safety in Adult Women with Lichen Sclerosus

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Sponsor:Leo Pharma A/S

Breast cancer

Not yet recruiting

Evaluation of Cefazolin versus Placebo for Preventing Surgical Site Infection in Breast Cancer Lumpectomy Patients

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cefazolin Sodium
  • Sponsor:University Hospital Of Clermont-Ferrand

Substances studied in this area

The therapies tested most often in Reproductive system and breast disorders trials.

Paclitaxel118 clinical trialsCarboplatin86 clinical trialsPembrolizumab76 clinical trialsLetrozole74 clinical trialsFulvestrant59 clinical trialsDocetaxel49 clinical trialsEnzalutamide49 clinical trialsExemestane47 clinical trialsAnastrozole45 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.